The recent announcement of PRT12396, a selective JH2 inhibitor targeting the JAK2V617F mutation, has shown promising potential in treating myeloproliferative neoplasms. This new drug is the first of its kind and has shown indications of modifying the disease. This development marks a significant advancement in the treatment of myeloproliferative neoplasms, affecting a substantial number of patients worldwide.